15:54 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious

INDICATION: HIV/AIDS Primate studies suggest combining CD4 mimetics with HIV gp120-based vaccines could help prevent HIV. In macaques challenged with simian human immunodeficiency virus (SHIV) immunized with HIV gp120 variants, a CD4 mimetic prevented infection in...
20:43 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Macaque studies suggest adding a boost containing five HIV gp120 variants to HIV vaccine regimens could help prevent infection by the virus. The boost consists of the adjuvant GLA-SE and five disease-associated...
17:17 , May 26, 2017 |  BC Week In Review  |  Clinical News

Inovio reports Phase I data for HIV vaccine Pennvax-GP

Inovio Pharmaceuticals Inc. (NASDAQ:INO) said data from the Phase I HVTN 098 trial in 94 healthy, HIV-uninfected volunteers showed that HIV vaccine Pennvax-GP produced "amongst the highest overall levels" of cellular and antibody immune response...
22:48 , May 24, 2017 |  BC Extra  |  Clinical News

Inovio gains on HIV vaccine data

Inovio Pharmaceuticals Inc. (NASDAQ:INO) gained $1.55 (22%) to $8.68 on Wednesday after it said data from a Phase I study in healthy volunteers showed that HIV vaccine Pennvax-GP produced "amongst the highest overall levels" of...
19:07 , Jan 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Cell culture studies suggest CRISPR-Cas9 editing of two or three HIV genes could help prevent reactivation of latent HIV in patients. In an HIV-1-infected human cell line expressing Cas9, lentiviral vector-encoded guide RNAs targeting...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

Pennvax-GP: Phase I started

Inovio said the HIV Vaccine Trials Network (HVTN) began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial of Pennvax-GP plus an IL-12 DNA adjuvant given via intradermal or intramuscular injection with electroporation at day...
07:00 , Jul 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: HIV env; HIV gag polyprotein; HIV pol; HIV gp140

Infectious disease INDICATION: HIV / AIDS Non-human primate studies identified a prime-boost vaccine protocol that could help prevent HIV infection. In a monkey model of SIV infection, two priming immunizations with an adenoviral vaccine encoding SIV env,...
08:00 , Nov 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS HIV gag polyprotein; HIV p27 (nef); HIV pol; HIV env Macaque studies suggest mosaic HIV...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Company News

DFH Pharma, Hetero Group deal

DFH partnered with Hetero to discover and develop second-generation HIV maturation inhibitors to treat all HIV strains. The compounds block maturation of the HIV gag polyprotein. Hetero will contribute medicinal chemistry, product development and...
23:32 , Apr 3, 2013 |  BC Extra  |  Company News

DFH, Hetero partner for HIV maturation inhibitors

DFH Pharma Inc. (Gaithersburg, Md.) partnered with Hetero Group (Hyderabad, India) to discover and develop second-generation HIV maturation inhibitors to treat all HIV strains. The compounds block maturation of the HIV gag polyprotein. Hetero will...